Xue, Jinyu
Emami, Bahman
Grimm, Jimm
Kubicek, Gregory J.
Asbell, Sucha O.
Lanciano, Rachelle
Welsh, James S.
Peng, Luke
Quon, Harry
Laub, Wolfram
Gui, Chengcheng
Spoleti, Nicholas
Das, Indra J.
Goldman, Howard Warren
Redmond, Kristin J.
Kleinberg, Lawrence R.
Brady, Luther W.
Article History
Received: 15 August 2018
Accepted: 15 November 2018
First Online: 3 December 2018
Compliance with ethical standards
:
: This work was partially supported by a grant from Accuray.
: Dr. Kleinberg has received research grants from Novocure, Arbor, Accuray, has performed consulting for Novocure, Accuray, and is on the advisory board for Novocure. Dr. Redmond has received research funding from Elekta AB and Accuray, as well as travel expenses and honorarium for speaking for Accuray. Dr. Grimm developed and holds intellectual property rights to the DVH Evaluator software tool which is an FDA-cleared product in commercial use, and which has been used for this analysis; and has received research grants from Novocure and Accuray. All other authors declare that they have no relevant conflict of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
: Informed consent was not applicable due to the retrospective nature of brain dose tolerance study. All other data was from the published literature.